Download PDF
Horm Metab Res 2017; 49(07): 485-492
DOI: 10.1055/s-0043-109562
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Parathyroid Hormone Levels Predict Long-Term Outcome After Operative Management of Parathyroid Cancer

Andreas Machens
1   Medical Faculty, Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Kerstin Lorenz
1   Medical Faculty, Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Henning Dralle
1   Medical Faculty, Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
2   Department of General, Visceral and Transplantation Surgery, Section of Endocrine Surgery, University of Duisburg-Essen, Essen, Germany
› Author Affiliations
Further Information

Publication History

received 18 December 2016

accepted 12 April 2017

Publication Date:
19 May 2017 (online)

Also available at
    Permissions and Reprints

Abstract

The role of parathyroid hormone (PTH) serum levels for prediction of outcome is ill defined for parathyroid cancer, which is a very rare disease. This investigation of 17 consecutive patients with parathyroid cancer, (re-)operated on at a tertiary referral center between 1994 and July 2016, with a mean follow-up of 179.6 months (15 years) aimed to clarify the suitability of PTH serum levels for prediction of clinical outcome after comprehensive operative management of parathyroid cancer. Cancer-specific mortality occurred significantly more often with the performance of sternotomy before or at first operation at this institution (80 vs. 0%; p=0.002); mean PTH serum levels before first operation (1 105 vs. 357 pg/ml; p=0.008; r=0.77) and at most recent follow-up (3 167 vs. 101 pg/ml; p=0.019; r=0.60); and normalization of PTH serum levels at most recent follow-up (0 vs. 64%; p=0.034). For cancer-specific survival, receiver-operating characteristics analysis identified as optimum cut-off point an initial PTH serum level of 700 pg/ml. For local recurrence, no significant associations were found. Kaplan-Meier analysis confirmed that the patients with initial PTH serum levels >700 pg/ml (plog-rank=0.011) and sternotomy (plog-rank<0.001), but not node or lung metastases, had worse cancer-specific survival. Parathyroid cancer is much more an endocrine disease with oncological features than an oncological disease with endocrine features. Operative intervention(s) should be comprehensive and directed at clearing all metabolically active parathyroid tumor deposits early. If surgical cure cannot be reached, it is pivotal to achieve metabolic control, obviating the need for, or facilitating, medical therapy of hypercalcemia, and preserve renal function.

Key words

parathyroid cancer - intact parathyroid hormone - lymph node metastasis - distant metastasis - locoregional recurrence - long-term survival
 

  • References

  • 1 Machens A, Lorenz K, Dralle H. Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations. J Clin Endocrinol Metab 2014; 99: E286-E292
    CrossrefPubMedSearch in Google Scholar
  • 2 Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 2000; 88: 2811-2816
    CrossrefPubMedSearch in Google Scholar
  • 3 Barbosa SL, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps JL, Caron P, Archambeaud-Mouveroux F, Conte-Devolx B, Rohmer V. Groupe d’Etude des Tumeurs Endocrines. Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid 2005; 15: 618-623
    CrossrefPubMedSearch in Google Scholar
  • 4 Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz Jr. EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 2004; 26: 716-726
    CrossrefPubMedSearch in Google Scholar
  • 5 Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007; 109: 1736-1741
    CrossrefPubMedSearch in Google Scholar
  • 6 Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, Evans DB, Winchester DP, Wang TS. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol 2004; 22: 3990-3995
    PubMedSearch in Google Scholar
  • 7 Hsu KT, Sippel RS, Chen H, Schneider DF. Is central lymph node dissection necessary for parathyroid carcinoma?. Surgery 2014; 156: 1336-1341 discussion 1341
    CrossrefPubMedSearch in Google Scholar
  • 8 Schneider DF. Parathyroid carcinoma: Is it time for change?. Ann Surg Oncol 2015; 22: 3772-3773
    CrossrefPubMedSearch in Google Scholar
  • 9 Erovic BM, Goldstein DP, Kim D, Mete O, Brierley J, Tsang R, Freeman JL, Asa SL, Rotstein L, Irish JC. Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck 2013; 35: 35-39
    CrossrefPubMedSearch in Google Scholar
  • 10 Goswamy J, Lei M, Simo R. Parathyroid carcinoma. Curr Opin Otolaryngol Head Neck Surg 2016; 24: 155-162
    CrossrefPubMedSearch in Google Scholar
  • 11 Schulte KM, Gill AJ, Barczynski M, Karakas E, Miyauchi A, Knoefel WT, Lombardi CP, Talat N, Diaz-Cano S, Grant CS. Classification of parathyroid cancer. Ann Surg Oncol 2012; 19: 2620-2628
    CrossrefPubMedSearch in Google Scholar
  • 12 Bondeson L, Grimelius L, Delellis RA. Parathyroid carcinoma. In: Delellis RS, Lloyd RV, Heitz PU. (eds.) World Health Organization classification of tumours, pathology and genetics: tumours of endocrine organs. Lyon: IARC Press; 2004
    Search in Google Scholar
  • 13 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
    CrossrefPubMedSearch in Google Scholar
  • 14 Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding ‘immortal time’ in the analysis of the treatment effects in observational studies. Kidney Int 2012; 81: 341-350
    CrossrefPubMedSearch in Google Scholar
  • 15 Frank-Raue K, Haag C, Schulze E, Keuser R, Raue F, Dralle H, Lorenz K. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. Eur J Endocrinol 2011; 165: 477-483
    CrossrefPubMedSearch in Google Scholar
  • 16 Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer 1999; 86: 378-380
    CrossrefPubMedSearch in Google Scholar
  • 17 Xue S, Chen H, Lv C, Shen X, Ding J, Liu J, Chen X. Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients. Clin Endocrinol 2016; 85: 29-36
    CrossrefPubMedSearch in Google Scholar
  • 18 Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: A National Cancer Data Base report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999; 86: 538-544
    CrossrefPubMedSearch in Google Scholar
  • 19 Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, Shen W, Gosnell J, Duh QY, Clark O. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab 2011; 96: 3679-3686
    CrossrefPubMedSearch in Google Scholar
  • 20 Sadler C, Gow KW, Beierle EA, Doski JJ, Langer M, Nuchtern JG, Vasudevan SA, Goldfarb M. Parathyroid carcinoma in more than 1000 patients: A population-level analysis. Surgery 2014; 156: 1622-1629 discussion 1629–1630
    CrossrefPubMedSearch in Google Scholar
  • 21 Young S, Wu JX, Li N, Yeh MW, Livhits MJ. More extensive surgery may not improve survival over parathyroidectomy alone in parathyroid carcinoma. Ann Surg Oncol 2016; 23: 2898-2904
    CrossrefPubMedSearch in Google Scholar
  • 22 Friedman LM, Furberg CD, DeMets DL. (eds.) Fundamentals of Clinical Trials. New York: Springer; 3rd ed. 1998
    Search in Google Scholar
  • 23 van Ballegooijen AJ, Rhee EP, Elmariah S, de Boer IH, Kestenbaum B. Renal clearance of mineral metabolism biomarkers. J Am Soc Nephrol 2016; 27: 392-397
    CrossrefPubMedSearch in Google Scholar